AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33555033
Drug: Ribociclib 400
RxNorm normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 400 mg daily, 3 weeks on and 1 week off
Trial: 33555265
Drug: START with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START with mobile augmentation
Trial: 33555436
Drug: In-hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital treatment for COVID-19 in patients < 65 years
Trial: 33555436
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to ICU and treatment with IMV in patients < 65 years
Trial: 33555777
Drug: Invasive mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive mechanical ventilation, vasoactive drugs, and new renal replacement therapy (n = 655)
Trial: 33555777
Drug: Discharge home
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discharge home (invasive mechanical ventilation, vasoactive drugs, and renal replacement)
Trial: 33556493
Drug: Palliative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative care intervention (PC) including a single in-person outpatient palliative care consultation (OPCC) plus 6 weekly, PC nurse coach-led telehealth sessions.
Trial: 33557591
Drug: hyperimmune anti-SARS-CoV-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
Trial: 33557844
Drug: 5-fluorouracile-based treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracile-based treatments (first- and second-line)
Trial: 33557844
Drug: Treatment withdrawal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment withdrawal and cancer progression
Trial: 33558125
Drug: Low-dose cone-beam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cone-beam CT angiography (5-second rotation, n=45)
Trial: 33558294
Drug: Micafungin 8
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 8 mg/kg daily for a mean of 13.3 days (±5.2 days)
Trial: 33558294
Drug: Micafungin 8
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 8 mg/kg daily
Trial: 33558436
Drug: Subcutaneous belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous belimumab 200 mg plus standard therapy
Trial: 33558725
Drug: T cells
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cells engineered with a T cell receptor targeting HPV-16 E7
Trial: 33559286
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment in DLBCL patients who are HBsAg positive
Trial: 33559286
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment in DLBCL patients who are HBsAg negative
Trial: 33559842
Drug: Twice-weekly 25-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly 25-mg prefilled liquid Yisaipu (group I)
Trial: 33559842
Drug: Once-weekly 50-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly 50-mg prefilled liquid Yisaipu (group II)
Trial: 33559842
Drug: Twice-weekly 25-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly 25-mg lyophilized Yisaipu (group III)
Trial: 33560097
Drug: Micafungin 150
RxNorm normalized name: micafungin 150 MG in 150 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 150 mg loading dose followed by 100 mg daily
Trial: 33560375
Drug: Multiagent initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent initial chemotherapy
Trial: 33560375
Drug: Multiagent initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent initial chemotherapy with anthracycline and etoposide
Trial: 33560394
Drug: IV copanlisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV copanlisib 60 mg on days 1, 8, and 15 of 28-day cycles for a median of 23 weeks
Trial: 33560399
Drug: Omidubicel in
RxNorm normalized name: omidubicel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omidubicel in combination with unmanipulated UCB graft
Trial: 33561011
Drug: Insulin deprivation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin deprivation for 5.4 ± 0.6 hours in T1D participants
Trial: 33561011
Drug: Insulin deprivation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin deprivation in T1D participants
Trial: 33561122
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol intake (additional 300 mg per day)
Trial: 33562091
Drug: Rifamycin SV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifamycin SV, 600 mg modified release tablets, taken three times a day for 14 days (total daily intake: 1800 mg)
Trial: 33563894
Drug: Panobinostat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (10 or 15 mg), lenalidomide 15 mg, bortezomib 1 mg/m²
Trial: 33565026
Drug: Lasmiditan 100
RxNorm normalized name: lasmiditan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan 100 mg (Cohort 1)
Trial: 33565026
Drug: Lasmiditan 200
RxNorm normalized name: lasmiditan 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasmiditan 200 mg (Cohort 2)
Trial: 33566467
Drug: Urinary (tissue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary (tissue inhibitor of metalloproteinases-2) × (insulin-like growth factor binding protein 7) test
Trial: 33567087
Drug: SARS-CoV-2-specific antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2-specific antibodies testing using VITROS Anti-SARS-CoV-2 IgG test
Trial: 33567192
Drug: Unilateral vestibular
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral vestibular implant (prosthesis)
Trial: 33567333
Drug: Ceftolozane/Tazobactam (C/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/Tazobactam (C/T) 3 g (ceftolozane 2 g/tazobactam 1 g) as a 60-minute intravenous infusion
Trial: 33568344
Drug: Atezolizumab (anti-PD-L1),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (anti-PD-L1), administered intravenously every 3 weeks until confirmed disease progression or loss of clinical benefit.
Trial: 33568345
Drug: Crizotinib at
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib at the recommended phase II dose of 280 mg/m²
Trial: 33568350
Drug: Additional immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional immune modulators (tumor necrosis factor-alpha inhibitor 77%, mycophenolate 23%) in addition to systemic steroids
Trial: 33568350
Drug: Additional immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional immune modulators
Trial: 33568360
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (10.8% at baseline, 46.5% moderate-intensity, 4.6% high-intensity)
Trial: 33568360
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (4.2% at baseline, increased to 41.6% at 3 months, decreased to 20.8% at 1 year, increased to 38.9% at 2 years)
Trial: 33568367
Drug: L-POCUS (lung
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-POCUS (lung point-of-care ultrasonography) performed within 48 hours following ED admission
Trial: 33568367
Drug: L-POCUS score
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-POCUS score assessment
Trial: 33568367
Drug: Second L-POCUS
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second L-POCUS performed at day 5±3
Trial: 33568367
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment as recommended by WHO
Trial: 33569214
Drug: Etoposide capsules
RxNorm normalized name: Etoposide Capsules
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide capsules (25 mg/50 mg) as maintenance therapy, once a day for 20 days, every 28 days until disease progression.
Trial: 33569214
Drug: Observation (non-maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (non-maintenance therapy, NMT) group.
Trial: 33569214
Drug: Etoposide capsules
RxNorm normalized name: Etoposide Capsules
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide capsules (25 mg) in stage I.
Trial: 33569311
Drug: RRx-001 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRx-001 treatment in combination with a platinum doublet
Trial: 33569311
Drug: RRx-001 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRx-001 treatment
Trial: 33569494
Drug: BI 1265162
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1265162 single doses ≤1200 µg
Trial: 33569494
Drug: BI 1265162
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1265162 multiple doses of 600 µg
Trial: 33570247
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PARP inhibitor (PARPi) and EZH2 inhibitor
Trial: 33571166
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pioglitazone and mirabegron
Trial: 33571520
Drug: Neogenin expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neogenin expression in DIPG tumors, specific dosage and duration not available
Trial: 33573594
Drug: Peer-led exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led exercise program, twice a week for 12 weeks, led by a trained leader of the same age.
Trial: 33574446
Drug: Intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiation therapy (IMRT) with a dose of 50 Gy (25 fractions of 2 Gy over 5 weeks)
Trial: 33574913
Drug: Sitagliptin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin combined with metformin (Sig)
Trial: 33574913
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (Ins)
Trial: 33734135
Drug: Entecavir therapy
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir therapy
Trial: 33576388
Drug: Criteria for
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Criteria for treatment futility
Trial: 33577756
Drug: Micropulse trans-scleral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micropulse trans-scleral laser therapy (mTLT)
Trial: 33578615
Drug: Navigated transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navigated transcranial magnetic stimulation (TMS) priming with transcranial direct current stimulation (tDCS) combined with constraint-induced movement therapy (CIMT)
Trial: 33579332
Drug: Attachment-Based Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-Based Family Therapy (ABFT) for 16 weeks, consisting of weekly therapy sessions (family/individual or both) according to the treatment manual.
Trial: 33579332
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU) for 16 weeks, not monitored.
Trial: 33579739
Drug: Atezolizumab and
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab and nab-paclitaxel (specific dosage and duration not mentioned)
Trial: 33579774
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFOT)
Trial: 33580779
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miRNA panel and hs-cTnT reference
Trial: 33581080
Drug: Tezacaftor-ivacaftor (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezacaftor-ivacaftor (oral tezacaftor 100 mg once daily and oral ivacaftor 150 mg once every 12 hours for up to 96 weeks)
Trial: 33581379
Drug: Accelerated rTMS
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated rTMS course (arTMS) of 6 sessions/day over 5 days (30 total) followed by tapering course of daily sessions (up to 25)
Trial: 33582392
Drug: Selective internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective internal radiation therapy
Trial: 33582418
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of mirogabalin
Trial: 33582418
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of pregabalin
Trial: 33585031
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8 mg/kg intravenously or 162 mg subcutaneously
Trial: 33585031
Drug: Corticosteroids (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (CS) methylprednisolone 80 mg/day
Trial: 33585503
Drug: Low Soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Soluble Receptor for Advanced Glycation End Products
Trial: 33585999
Drug: Ruxolitinib (10-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10-25 mg bid) in combination with weekly paclitaxel (80 mg/m)
Trial: 33586174
Drug: Narrowband ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband ultraviolet B (NB-UVB) treatment for 36 sessions
Trial: 33586174
Drug: Narrowband ultraviolet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband ultraviolet B (NB-UVB) treatment
Trial: 33586581
Drug: Bendamustine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 200 mg/m²
Trial: 33586590
Drug: RO6870810 (BET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6870810 (BET inhibitor)
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus in collagen-elastin matrices
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on Staphylococcus aureus on dermal samples
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment for 2 min on human dermal samples
Trial: 33587156
Drug: Repeated daily
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated daily CAP treatments for 2 min on dermal samples
Trial: 33587156
Drug: Repeated CAP
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated CAP treatment for 2 min on ex vivo human burn wound models
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment for 3× 20" on intact skin of volunteers
Trial: 33587156
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) treatment on intact skin of 15 volunteers contaminated with Pseudomonas aeruginosa
Trial: 33587156
Drug: Lowering the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering the plasma power during CAP treatment
Trial: 33587435
Drug: Sofosbuvir-based DAA
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-based DAA therapy + Ribavirin (RBV)
Trial: 36686592
Drug: Sofosbuvir-based DAA
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir-based DAA therapy
Trial: 33588149
Drug: ABTL0812 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 at 1300 mg three times a day (RP2D)
Trial: 33588149
Drug: ABTL0812 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABTL0812 at 500 mg once a day to 2000 mg twice a day (escalation phase)
Trial: 33588922
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days.
Trial: 33588922
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg intravenously
Trial: 33588925
Drug: cDPP3 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cDPP3 levels > 40.4 ng/mL upon admission
Trial: 33589404
Drug: Higher insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher insulin concentration
Trial: 33589538
Drug: Intensive arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive arm motor therapy
Trial: 33589714
Drug: Multi-domain program
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-domain program (24-week, bi-weekly) including dual-task exercises, cognitive training, and mobile application-based nutritional guidance
Trial: 33590273
Drug: bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus injection of LAT-1 targeting PET tracer
Trial: 33591016
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of cerebral tissue oxygen saturation desaturation
Trial: 33591143
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric bupivacaine with 20 μg of fentanyl
Trial: 33591291
Drug: Nonpharmacological interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonpharmacological interventions administered by a comfort coach
Trial: 33591402
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment for pediatric renal tumors (e.g., bilateral Wilms tumor)
Trial: 33591402
Drug: Targeted and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted and immune therapies
Trial: 33591468
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg oral daily) plus trastuzumab (6 mg/kg intravenous every 21 days)
Trial: 33593135
Drug: Sublingual tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual tacrolimus 0.04 mg/kg/dose twice daily
Trial: 33593135
Drug: Oral tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tacrolimus (after sublingual administration)
Trial: 33593311
Drug: FOLFIRINOX (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) and hypofractionated SBRT (5 fractions, total dose of 30 Gy with simultaneous integrated boost of 50 Gy on tumor-vessel interface) followed by IORT (10 Gy)
Trial: 33593430
Drug: RBX2660 (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBX2660 (one or two doses)
Trial: 33593448
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus monotherapy (every 2 months)
Trial: 33593448
Drug: Anti-vascular endothelial
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vascular endothelial growth factor (VEGF) (monthly)
Trial: 33593448
Drug: Intravitreal sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal sirolimus monotherapy
Trial: 33593763
Drug: Clinical characteristics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical characteristics, including demographics, pathology, treatment and prognosis of patients with GBC in China